Pirlindole

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pirlindole
Accession Number
DB09244
Type
Small Molecule
Groups
Approved
Description

Pirlindole is a reversible inhibitor of monoamine oxidase A (RIMA) which was developed and is used in Russia as an antidepressant. It is structurally and pharmacologically related to metralindole.

Structure
Thumb
Synonyms
Not Available
International/Other Brands
Lifril / Pyrazidol
Categories
UNII
V39YPH45FZ
CAS number
60762-57-4
Weight
Average: 226.323
Monoisotopic: 226.146998588
Chemical Formula
C15H18N2
InChI Key
IWVRVEIKCBFZNF-UHFFFAOYSA-N
InChI
InChI=1S/C15H18N2/c1-10-5-6-14-12(9-10)11-3-2-4-13-15(11)17(14)8-7-16-13/h5-6,9,13,16H,2-4,7-8H2,1H3
IUPAC Name
12-methyl-1,4-diazatetracyclo[7.6.1.0⁵,¹⁶.0¹⁰,¹⁵]hexadeca-9(16),10,12,14-tetraene
SMILES
CC1=CC=C2N3CCNC4CCCC(=C34)C2=C1

Pharmacology

Indication

For the treatment of depression.

Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetaminePirlindole may increase the hypertensive activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePirlindole may increase the hypertensive activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePirlindole may increase the hypertensive activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolinePirlindole may increase the hypertensive activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcarbosePirlindole may increase the hypoglycemic activities of Acarbose.Approved, Investigational
AcebutololPirlindole may increase the hypotensive activities of Acebutolol.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Pirlindole.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Pirlindole.Experimental
AlaproclateThe risk or severity of adverse effects can be increased when Alaproclate is combined with Pirlindole.Experimental
AlbiglutidePirlindole may increase the hypoglycemic activities of Albiglutide.Approved
AlfentanilAlfentanil may increase the serotonergic activities of Pirlindole.Approved, Illicit
AliskirenPirlindole may increase the hypotensive activities of Aliskiren.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Pirlindole.Approved, Investigational
AlogliptinPirlindole may increase the hypoglycemic activities of Alogliptin.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Pirlindole.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Alphaprodine is combined with Pirlindole.Illicit
AlprenololPirlindole may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AltretamineAltretamine may increase the orthostatic hypotensive activities of Pirlindole.Approved
AmbrisentanPirlindole may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmineptinePirlindole may increase the serotonergic activities of Amineptine.Illicit, Withdrawn
AmitriptylinePirlindole may increase the serotonergic activities of Amitriptyline.Approved
AmlodipinePirlindole may increase the hypotensive activities of Amlodipine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Amoxapine.Approved
AmphetaminePirlindole may increase the hypertensive activities of Amphetamine.Approved, Illicit
ApomorphineThe metabolism of Apomorphine can be decreased when combined with Pirlindole.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Apraclonidine.Approved
ArbutamineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Arformoterol.Approved, Investigational
AtenololPirlindole may increase the hypotensive activities of Atenolol.Approved
AtomoxetinePirlindole may increase the central neurotoxic activities of Atomoxetine.Approved
AtropinePirlindole may increase the hypertensive activities of Atropine.Approved, Vet Approved
BambuterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Bambuterol.Approved, Investigational
BenazeprilPirlindole may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazidePirlindole may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinPirlindole may increase the hypertensive activities of Benmoxin.Withdrawn
BenzphetaminePirlindole may increase the hypertensive activities of Benzphetamine.Approved, Illicit
BepridilPirlindole may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BetahistineThe serum concentration of Betahistine can be increased when it is combined with Pirlindole.Approved
BetaxololPirlindole may increase the hypotensive activities of Betaxolol.Approved
BethanidinePirlindole may increase the hypotensive activities of Bethanidine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Pirlindole.Approved, Investigational
BezafibrateThe risk or severity of adverse effects can be increased when Pirlindole is combined with Bezafibrate.Approved
BietaserpinePirlindole may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostPirlindole may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololPirlindole may increase the hypotensive activities of Bisoprolol.Approved
BosentanPirlindole may increase the hypotensive activities of Bosentan.Approved, Investigational
BQ-123Pirlindole may increase the hypotensive activities of BQ-123.Investigational
BretyliumPirlindole may increase the hypotensive activities of Bretylium.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Brimonidine.Approved
BrofarominePirlindole may increase the hypertensive activities of Brofaromine.Experimental
BromocriptinePirlindole may increase the hypoglycemic activities of Bromocriptine.Approved, Investigational
BupranololPirlindole may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Pirlindole.Approved, Illicit, Investigational, Vet Approved
BupropionPirlindole may increase the hypertensive activities of Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Pirlindole.Approved, Investigational
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Pirlindole.Approved, Illicit, Vet Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Pirlindole.Approved
CabergolineThe metabolism of Cabergoline can be decreased when combined with Pirlindole.Approved
CadralazinePirlindole may increase the hypotensive activities of Cadralazine.Experimental
CafedrinePirlindole may increase the hypotensive activities of Cafedrine.Investigational
CanagliflozinPirlindole may increase the hypoglycemic activities of Canagliflozin.Approved
Candesartan cilexetilPirlindole may increase the hypotensive activities of Candesartan.Approved
CandoxatrilPirlindole may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilPirlindole may increase the hypotensive activities of Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pirlindole.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Pirlindole.Illicit, Investigational, Vet Approved
CaroxazonePirlindole may increase the hypertensive activities of Caroxazone.Withdrawn
CarteololPirlindole may increase the hypotensive activities of Carteolol.Approved
CarvedilolPirlindole may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololPirlindole may increase the hypotensive activities of Celiprolol.Approved, Investigational
ChlorothiazidePirlindole may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorphenterminePirlindole may increase the hypertensive activities of Chlorphentermine.Illicit, Withdrawn
ChlorpropamidePirlindole may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidonePirlindole may increase the hypotensive activities of Chlorthalidone.Approved
CicletaninePirlindole may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilPirlindole may increase the hypotensive activities of Cilazapril.Approved
CirazolinePirlindole may increase the hypertensive activities of Cirazoline.Experimental
CitalopramPirlindole may increase the serotonergic activities of Citalopram.Approved
ClemastinePirlindole may increase the anticholinergic activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClomipraminePirlindole may increase the serotonergic activities of Clomipramine.Approved, Vet Approved
ClonidinePirlindole may increase the hypotensive activities of Clonidine.Approved
CloranololPirlindole may increase the hypotensive activities of Cloranolol.Experimental
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Pirlindole.Approved, Illicit
CryptenaminePirlindole may increase the hypotensive activities of Cryptenamine.Approved
CyclobenzaprineCyclobenzaprine may increase the serotonergic activities of Pirlindole.Approved
CyclopenthiazidePirlindole may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Pirlindole.Approved, Investigational
CyclothiazidePirlindole may increase the hypotensive activities of Cyclothiazide.Approved
CymarinCymarin may decrease the cardiotoxic activities of Pirlindole.Experimental
CyproheptadinePirlindole may increase the anticholinergic activities of Cyproheptadine.Approved
DapagliflozinPirlindole may increase the hypoglycemic activities of Dapagliflozin.Approved
DapoxetinePirlindole may increase the serotonergic activities of Dapoxetine.Investigational
DebrisoquinPirlindole may increase the hypotensive activities of Debrisoquin.Approved, Investigational
DelaprilPirlindole may increase the hypotensive activities of Delapril.Experimental
DeserpidinePirlindole may increase the hypotensive activities of Deserpidine.Approved
DesipraminePirlindole may increase the serotonergic activities of Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Pirlindole.Approved
DesvenlafaxinePirlindole may increase the serotonergic activities of Desvenlafaxine.Approved
DexmethylphenidatePirlindole may increase the hypertensive activities of Dexmethylphenidate.Approved
DextroamphetaminePirlindole may increase the hypertensive activities of Dextroamphetamine.Approved, Illicit
DextromethorphanPirlindole may increase the serotonergic activities of Dextromethorphan.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Pirlindole.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pirlindole.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Pirlindole.Approved, Investigational
DiazoxidePirlindole may increase the hypotensive activities of Diazoxide.Approved
DibenzepinPirlindole may increase the serotonergic activities of Dibenzepin.Experimental
diethylnorsperminePirlindole may increase the hypotensive activities of diethylnorspermine.Investigational
DiethylpropionPirlindole may increase the hypertensive activities of Diethylpropion.Approved, Illicit
DigitoxinDigitoxin may decrease the cardiotoxic activities of Pirlindole.Approved, Investigational
DigoxinDigoxin may decrease the cardiotoxic activities of Pirlindole.Approved
DihydralazinePirlindole may increase the hypotensive activities of Dihydralazine.Investigational
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Pirlindole.Approved, Illicit
DihydroergotamineThe metabolism of Dihydroergotamine can be decreased when combined with Pirlindole.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Pirlindole.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Pirlindole.Experimental, Illicit
DiltiazemPirlindole may increase the hypotensive activities of Diltiazem.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Pirlindole.Approved, Illicit
DipivefrinThe risk or severity of adverse effects can be increased when Pirlindole is combined with Dipivefrin.Approved
DisopyramidePirlindole may increase the hypoglycemic activities of Disopyramide.Approved
DobutamineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Dobutamine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Pirlindole.Approved, Investigational
DomperidoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Domperidone.Approved, Investigational, Vet Approved
DorzolamidePirlindole may increase the hypotensive activities of Dorzolamide.Approved
DosulepinPirlindole may increase the serotonergic activities of Dosulepin.Approved
DoxapramPirlindole may increase the hypertensive activities of Doxapram.Approved, Vet Approved
DoxazosinPirlindole may increase the hypotensive activities of Doxazosin.Approved
DoxepinPirlindole may increase the serotonergic activities of Doxepin.Approved
DoxylaminePirlindole may increase the anticholinergic activities of Doxylamine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Pirlindole.Investigational
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Pirlindole.Experimental, Illicit
DroxidopaThe risk or severity of adverse effects can be increased when Pirlindole is combined with Droxidopa.Approved, Investigational
DulaglutidePirlindole may increase the hypoglycemic activities of Dulaglutide.Approved
DuloxetinePirlindole may increase the serotonergic activities of Duloxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Pirlindole.Experimental, Illicit
EfonidipinePirlindole may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Pirlindole.Approved, Investigational
EmpagliflozinPirlindole may increase the hypoglycemic activities of Empagliflozin.Approved
EnalaprilPirlindole may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatPirlindole may increase the hypotensive activities of Enalaprilat.Approved
EndralazinePirlindole may increase the hypotensive activities of Endralazine.Experimental
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Pirlindole.Approved, Investigational
EpanololPirlindole may increase the hypotensive activities of Epanolol.Experimental
EphedraThe risk or severity of adverse effects can be increased when Pirlindole is combined with Ephedra.Approved, Nutraceutical, Withdrawn
EpoprostenolPirlindole may increase the hypotensive activities of Epoprostenol.Approved
EprosartanPirlindole may increase the hypotensive activities of Eprosartan.Approved
ErgotaminePirlindole may increase the hypertensive activities of Ergotamine.Approved
EscitalopramPirlindole may increase the serotonergic activities of Escitalopram.Approved, Investigational
EsmirtazapinePirlindole may increase the serotonergic activities of Esmirtazapine.Investigational
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Pirlindole.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Pirlindole.Approved, Illicit
EtoperidonePirlindole may increase the serotonergic activities of Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Pirlindole.Illicit, Vet Approved
ExenatidePirlindole may increase the hypoglycemic activities of Exenatide.Approved, Investigational
FelodipinePirlindole may increase the hypotensive activities of Felodipine.Approved, Investigational
FenfluramineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamPirlindole may increase the hypotensive activities of Fenoldopam.Approved
FenoterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Fenoterol.Approved, Investigational
FentanylFentanyl may increase the serotonergic activities of Pirlindole.Approved, Illicit, Investigational, Vet Approved
Ferulic acidPirlindole may increase the hypotensive activities of Ferulic acid.Experimental
FluoxetinePirlindole may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FluvoxaminePirlindole may increase the serotonergic activities of Fluvoxamine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Formoterol.Approved, Investigational
FosinoprilPirlindole may increase the hypotensive activities of Fosinopril.Approved
FrovatriptanThe metabolism of Frovatriptan can be decreased when combined with Pirlindole.Approved, Investigational
FurazolidonePirlindole may increase the hypertensive activities of Furazolidone.Approved, Investigational, Vet Approved
GepefrineThe risk or severity of adverse effects can be increased when Gepefrine is combined with Pirlindole.Experimental
GitoformateGitoformate may decrease the cardiotoxic activities of Pirlindole.Experimental
GliclazidePirlindole may increase the hypoglycemic activities of Gliclazide.Approved
GlimepiridePirlindole may increase the hypoglycemic activities of Glimepiride.Approved
GlipizidePirlindole may increase the hypoglycemic activities of Glipizide.Approved
GlyburidePirlindole may increase the hypoglycemic activities of Glyburide.Approved
GuanabenzPirlindole may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelPirlindole may increase the hypotensive activities of Guanadrel.Approved
GuanazodinePirlindole may increase the hypotensive activities of Guanazodine.Experimental
GuanethidinePirlindole may increase the hypotensive activities of Guanethidine.Approved
GuanfacinePirlindole may increase the hypotensive activities of Guanfacine.Approved, Investigational
GuanoclorPirlindole may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzPirlindole may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanPirlindole may increase the hypotensive activities of Guanoxan.Experimental
HarmalinePirlindole may increase the hypertensive activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Pirlindole.Approved, Illicit, Investigational
HexamethoniumPirlindole may increase the hypotensive activities of Hexamethonium.Experimental
HydracarbazinePirlindole may increase the hypertensive activities of Hydracarbazine.Experimental
HydralazinePirlindole may increase the hypotensive activities of Hydralazine.Approved
HydrochlorothiazidePirlindole may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydrocodone.Approved, Illicit
HydroflumethiazidePirlindole may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Hydromorphone.Approved, Illicit
HydroxyamphetaminePirlindole may increase the hypertensive activities of Hydroxyamphetamine.Approved
ImidaprilPirlindole may increase the hypotensive activities of Imidapril.Investigational
ImipraminePirlindole may increase the serotonergic activities of Imipramine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Indacaterol.Approved
IndalpinePirlindole may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamidePirlindole may increase the hypotensive activities of Indapamide.Approved
IndenololPirlindole may increase the hypotensive activities of Indenolol.Withdrawn
IndoraminPirlindole may increase the hypotensive activities of Indoramin.Withdrawn
Insulin AspartPirlindole may increase the hypoglycemic activities of Insulin Aspart.Approved
Insulin DetemirPirlindole may increase the hypoglycemic activities of Insulin Detemir.Approved
Insulin GlarginePirlindole may increase the hypoglycemic activities of Insulin Glargine.Approved
Insulin GlulisinePirlindole may increase the hypoglycemic activities of Insulin Glulisine.Approved
Insulin HumanPirlindole may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin LisproPirlindole may increase the hypoglycemic activities of Insulin Lispro.Approved
Iofetamine I-123The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Pirlindole.Approved
IprindolePirlindole may increase the serotonergic activities of Iprindole.Experimental
IproclozidePirlindole may increase the hypertensive activities of Iproclozide.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Pirlindole.Withdrawn
IrbesartanPirlindole may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Pirlindole.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Isoetarine.Approved
IsomethepteneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Isometheptene.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Isoprenaline.Approved
IsradipinePirlindole may increase the hypotensive activities of Isradipine.Approved
KetanserinPirlindole may increase the hypotensive activities of Ketanserin.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Pirlindole.Approved, Investigational
L-TryptophanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pirlindole.Approved, Nutraceutical, Withdrawn
LabetalolPirlindole may increase the hypotensive activities of Labetalol.Approved
LacidipinePirlindole may increase the hypotensive activities of Lacidipine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Pirlindole.Experimental
LatanoprostPirlindole may increase the hypotensive activities of Latanoprost.Approved, Investigational
LercanidipinePirlindole may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Pirlindole.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Pirlindole.Approved, Investigational
LevomilnacipranPirlindole may increase the serotonergic activities of Levomilnacipran.Approved
LevonordefrinPirlindole may increase the hypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Pirlindole.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Levosalbutamol.Approved
LinezolidThe risk or severity of adverse effects can be increased when Pirlindole is combined with Linezolid.Approved, Investigational
LinsidominePirlindole may increase the hypotensive activities of Linsidomine.Experimental
LiraglutidePirlindole may increase the hypoglycemic activities of Liraglutide.Approved
LisdexamfetaminePirlindole may increase the hypertensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilPirlindole may increase the hypotensive activities of Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Pirlindole.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Pirlindole is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Pirlindole.Illicit
LofepraminePirlindole may increase the serotonergic activities of Lofepramine.Experimental
LofexidinePirlindole may increase the hypotensive activities of Lofexidine.Approved, Investigational
LosartanPirlindole may increase the hypotensive activities of Losartan.Approved
MacitentanPirlindole may increase the hypotensive activities of Macitentan.Approved
ManidipinePirlindole may increase the hypotensive activities of Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Pirlindole.Approved
MebanazinePirlindole may increase the hypertensive activities of Mebanazine.Withdrawn
MecamylaminePirlindole may increase the hypotensive activities of Mecamylamine.Approved
MecaserminPirlindole may increase the hypoglycemic activities of Mecasermin.Approved, Investigational
MephedronePirlindole may increase the hypertensive activities of Mephedrone.Investigational
MephenterminePirlindole may increase the hypertensive activities of Mephentermine.Approved
MeptazinolThe risk or severity of adverse effects can be increased when Meptazinol is combined with Pirlindole.Experimental
MequitazinePirlindole may increase the anticholinergic activities of Mequitazine.Approved
MetaraminolPirlindole may increase the hypertensive activities of Metaraminol.Approved, Investigational
MetforminPirlindole may increase the hypoglycemic activities of Metformin.Approved
MethadoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Pirlindole.Approved, Illicit
MethamphetaminePirlindole may increase the hypertensive activities of Methamphetamine.Approved, Illicit
MethoserpidinePirlindole may increase the hypotensive activities of Methoserpidine.Experimental
MethoxaminePirlindole may increase the hypertensive activities of Methoxamine.Approved, Investigational
MethoxyphenamineThe risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Pirlindole.Experimental
MethyldopaThe risk or severity of adverse effects can be increased when Pirlindole is combined with Methyldopa.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methylecgonine is combined with Pirlindole.Experimental
Methylene bluePirlindole may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidatePirlindole may increase the hypertensive activities of Methylphenidate.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Pirlindole.Experimental
MetipranololPirlindole may increase the hypotensive activities of Metipranolol.Approved
MetolazonePirlindole may increase the hypotensive activities of Metolazone.Approved
MetoprololPirlindole may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosinePirlindole may increase the hypotensive activities of Metyrosine.Approved
MianserinPirlindole may increase the neurotoxic activities of Mianserin.Approved, Investigational
MibefradilPirlindole may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MidodrinePirlindole may increase the hypertensive activities of Midodrine.Approved
MidomafetaminePirlindole may increase the hypertensive activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit, Investigational
MifepristonePirlindole may increase the hypoglycemic activities of Mifepristone.Approved, Investigational
MiglitolPirlindole may increase the hypoglycemic activities of Miglitol.Approved
MilnacipranPirlindole may increase the serotonergic activities of Milnacipran.Approved
MinaprineMinaprine may increase the hypertensive activities of Pirlindole.Approved
MinoxidilPirlindole may increase the hypotensive activities of Minoxidil.Approved
MirtazapinePirlindole may increase the central neurotoxic activities of Mirtazapine.Approved
MMDAPirlindole may increase the hypertensive activities of MMDA.Experimental, Illicit
MoclobemideThe risk or severity of adverse effects can be increased when Pirlindole is combined with Moclobemide.Approved
MoexiprilPirlindole may increase the hypotensive activities of Moexipril.Approved
MoxonidinePirlindole may increase the hypotensive activities of Moxonidine.Approved, Investigational
MuzoliminePirlindole may increase the hypotensive activities of Muzolimine.Experimental
NadololPirlindole may increase the hypotensive activities of Nadolol.Approved
NaftopidilPirlindole may increase the hypotensive activities of Naftopidil.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Pirlindole.Approved
NaratriptanThe metabolism of Naratriptan can be decreased when combined with Pirlindole.Approved, Investigational
NateglinidePirlindole may increase the hypoglycemic activities of Nateglinide.Approved, Investigational
NebivololPirlindole may increase the hypotensive activities of Nebivolol.Approved, Investigational
NefazodonePirlindole may increase the serotonergic activities of Nefazodone.Approved, Withdrawn
NialamideNialamide may increase the hypertensive activities of Pirlindole.Withdrawn
NicardipinePirlindole may increase the hypotensive activities of Nicardipine.Approved
NicorandilPirlindole may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipinePirlindole may increase the hypotensive activities of Niguldipine.Experimental
NilvadipinePirlindole may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimodipinePirlindole may increase the hypotensive activities of Nimodipine.Approved
NisoldipinePirlindole may increase the hypotensive activities of Nisoldipine.Approved
NitrendipinePirlindole may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroprussidePirlindole may increase the hypotensive activities of Nitroprusside.Approved
NorepinephrinePirlindole may increase the hypertensive activities of Norepinephrine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Pirlindole.Approved, Illicit
NortriptylinePirlindole may increase the serotonergic activities of Nortriptyline.Approved
OctamoxinPirlindole may increase the hypertensive activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Olanzapine.Approved, Investigational
OleandrinOleandrin may decrease the cardiotoxic activities of Pirlindole.Experimental, Investigational
OlmesartanPirlindole may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlodaterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Olodaterol.Approved
OmapatrilatPirlindole may increase the hypotensive activities of Omapatrilat.Investigational
OpipramolPirlindole may increase the serotonergic activities of Opipramol.Investigational
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Pirlindole.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Orciprenaline.Approved
OuabainOuabain may decrease the cardiotoxic activities of Pirlindole.Approved
OxprenololPirlindole may increase the hypotensive activities of Oxprenolol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Pirlindole.Approved, Investigational, Vet Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Pirlindole.Approved, Vet Approved
PargylinePirlindole may increase the hypotensive activities of Pargyline.Approved
ParoxetinePirlindole may increase the serotonergic activities of Paroxetine.Approved, Investigational
PenbutololPirlindole may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidinePirlindole may increase the hypoglycemic activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Pirlindole.Approved, Vet Approved
PentoliniumPirlindole may increase the hypotensive activities of Pentolinium.Approved
PergolideThe metabolism of Pergolide can be decreased when combined with Pirlindole.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilPirlindole may increase the hypotensive activities of Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Pirlindole.Experimental
PethidinePirlindole may increase the serotonergic activities of Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Phenazocine is combined with Pirlindole.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Pirlindole.Approved
PheniprazinePirlindole may increase the hypertensive activities of Pheniprazine.Withdrawn
PhenoperidineThe risk or severity of adverse effects can be increased when Phenoperidine is combined with Pirlindole.Experimental
PhenoxybenzaminePirlindole may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePirlindole may increase the hypertensive activities of Phenoxypropazine.Withdrawn
PhenterminePirlindole may increase the hypertensive activities of Phentermine.Approved, Illicit
PhentolaminePirlindole may increase the hypotensive activities of Phentolamine.Approved
PhenylephrinePirlindole may increase the hypertensive activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PholcodinePholcodine may increase the serotonergic activities of Pirlindole.Approved, Illicit
PiclozotanThe metabolism of Piclozotan can be decreased when combined with Pirlindole.Investigational
PinacidilPirlindole may increase the hypotensive activities of Pinacidil.Withdrawn
PindololPirlindole may increase the hypotensive activities of Pindolol.Approved
PioglitazonePirlindole may increase the hypoglycemic activities of Pioglitazone.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Piritramide is combined with Pirlindole.Investigational
PivhydrazinePirlindole may increase the hypertensive activities of Pivhydrazine.Withdrawn
PizotifenPirlindole may increase the anticholinergic activities of Pizotifen.Approved
PolythiazidePirlindole may increase the hypotensive activities of Polythiazide.Approved
PramlintidePirlindole may increase the hypoglycemic activities of Pramlintide.Approved, Investigational
PrazosinPirlindole may increase the hypotensive activities of Prazosin.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Procaterol.Approved, Investigational
PropranololPirlindole may increase the hypotensive activities of Propranolol.Approved, Investigational
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Pirlindole.Experimental
ProtriptylinePirlindole may increase the serotonergic activities of Protriptyline.Approved
PRX-00023The metabolism of PRX-00023 can be decreased when combined with Pirlindole.Investigational
PseudoephedrinePirlindole may increase the hypertensive activities of Pseudoephedrine.Approved
QuinaprilPirlindole may increase the hypotensive activities of Quinapril.Approved, Investigational
QuininePirlindole may increase the hypoglycemic activities of Quinine.Approved
RamiprilPirlindole may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypertensive activities of Pirlindole.Approved
RemifentanilRemifentanil may increase the serotonergic activities of Pirlindole.Approved
RemikirenPirlindole may increase the hypotensive activities of Remikiren.Approved
RepaglinidePirlindole may increase the hypoglycemic activities of Repaglinide.Approved, Investigational
RescinnaminePirlindole may increase the hypotensive activities of Rescinnamine.Approved
ReserpineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Reserpine.Approved, Investigational
RilmenidinePirlindole may increase the hypotensive activities of Rilmenidine.Investigational
RiociguatPirlindole may increase the hypotensive activities of Riociguat.Approved
RitobegronPirlindole may increase the hypertensive activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Ritodrine.Approved, Investigational
RizatriptanThe metabolism of Rizatriptan can be decreased when combined with Pirlindole.Approved
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Pirlindole.Approved, Investigational
RosiglitazonePirlindole may increase the hypoglycemic activities of Rosiglitazone.Approved, Investigational
SafrazinePirlindole may increase the hypertensive activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Salmeterol.Approved
SaprisartanPirlindole may increase the hypotensive activities of Saprisartan.Experimental
SaxagliptinPirlindole may increase the hypoglycemic activities of Saxagliptin.Approved
SelegilineSelegiline may increase the hypertensive activities of Pirlindole.Approved, Investigational, Vet Approved
SelexipagPirlindole may increase the hypotensive activities of Selexipag.Approved
SertralinePirlindole may increase the serotonergic activities of Sertraline.Approved
SitagliptinPirlindole may increase the hypoglycemic activities of Sitagliptin.Approved, Investigational
SitaxentanPirlindole may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
SpiraprilPirlindole may increase the hypotensive activities of Spirapril.Approved
SufentanilSufentanil may increase the serotonergic activities of Pirlindole.Approved, Investigational
SulfadiazinePirlindole may increase the hypoglycemic activities of Sulfadiazine.Approved, Vet Approved
SulfamethoxazolePirlindole may increase the hypoglycemic activities of Sulfamethoxazole.Approved
SulfisoxazolePirlindole may increase the hypoglycemic activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe metabolism of Sumatriptan can be decreased when combined with Pirlindole.Approved, Investigational
SunitinibPirlindole may increase the hypoglycemic activities of Sunitinib.Approved, Investigational
TalinololPirlindole may increase the hypotensive activities of Talinolol.Investigational
TapentadolThe risk or severity of adverse effects can be increased when Tapentadol is combined with Pirlindole.Approved
TelmisartanPirlindole may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilPirlindole may increase the hypotensive activities of Temocapril.Experimental, Investigational
TerbutalineThe risk or severity of adverse effects can be increased when Pirlindole is combined with Terbutaline.Approved
TerlipressinPirlindole may increase the hypotensive activities of Terlipressin.Approved, Investigational
Testosterone PropionateThe risk or severity of adverse effects can be increased when Testosterone Propionate is combined with Pirlindole.Approved, Vet Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Pirlindole.Approved
TetrahydropalmatinePirlindole may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TetryzolinePirlindole may increase the hypertensive activities of Tetryzoline.Approved
TheodrenalinePirlindole may increase the hypotensive activities of Theodrenaline.Investigational
TianeptineThe risk or severity of adverse effects can be increased when Tianeptine is combined with Pirlindole.Approved, Investigational
TibolonePirlindole may increase the hypotensive activities of Tibolone.Approved, Investigational
TicrynafenPirlindole may increase the hypotensive activities of Ticrynafen.Withdrawn
TilidineThe risk or severity of adverse effects can be increased when Tilidine is combined with Pirlindole.Experimental
TimololPirlindole may increase the hypotensive activities of Timolol.Approved
TolazamidePirlindole may increase the hypoglycemic activities of Tolazamide.Approved
TolazolinePirlindole may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamidePirlindole may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Pirlindole.Approved, Withdrawn
TolonidinePirlindole may increase the hypotensive activities of Tolonidine.Experimental
ToloxatonePirlindole may increase the hypertensive activities of Toloxatone.Approved
TorasemidePirlindole may increase the hypotensive activities of Torasemide.Approved
TramadolTramadol may increase the neuroexcitatory activities of Pirlindole.Approved, Investigational
TrandolaprilPirlindole may increase the hypotensive activities of Trandolapril.Approved
Trans-2-PhenylcyclopropylaminePirlindole may increase the hypertensive activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Pirlindole.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Pirlindole.Approved, Investigational
TravoprostPirlindole may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Pirlindole is combined with Trazodone.Approved, Investigational
TreprostinilPirlindole may increase the hypotensive activities of Treprostinil.Approved, Investigational
TrichlormethiazidePirlindole may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrimazosinPirlindole may increase the hypotensive activities of Trimazosin.Experimental
TrimethaphanPirlindole may increase the hypotensive activities of Trimethaphan.Approved, Investigational
TrimipraminePirlindole may increase the serotonergic activities of Trimipramine.Approved
UnoprostonePirlindole may increase the hypotensive activities of Unoprostone.Approved
UrapidilPirlindole may increase the hypotensive activities of Urapidil.Investigational
ValsartanPirlindole may increase the hypotensive activities of Valsartan.Approved, Investigational
VenlafaxinePirlindole may increase the serotonergic activities of Venlafaxine.Approved
VilanterolThe risk or severity of adverse effects can be increased when Pirlindole is combined with Vilanterol.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Pirlindole.Approved
VincaminePirlindole may increase the hypotensive activities of Vincamine.Experimental
VinpocetinePirlindole may increase the hypotensive activities of Vinpocetine.Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Pirlindole.Approved
XipamidePirlindole may increase the hypotensive activities of Xipamide.Experimental
XylometazolinePirlindole may increase the hypotensive activities of Xylometazoline.Approved
ZimelidinePirlindole may increase the serotonergic activities of Zimelidine.Withdrawn
ZofenoprilPirlindole may increase the hypotensive activities of Zofenopril.Experimental
ZolmitriptanThe metabolism of Zolmitriptan can be decreased when combined with Pirlindole.Approved, Investigational
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Drug
D08392
PubChem Compound
68802
PubChem Substance
310265147
ChemSpider
62039
ChEBI
91755
ChEMBL
CHEMBL32350
Wikipedia
Pirlindole

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.107 mg/mLALOGPS
logP2.1ALOGPS
logP3.1ChemAxon
logS-3.3ALOGPS
pKa (Strongest Basic)8.38ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area16.96 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity70.42 m3·mol-1ChemAxon
Polarizability27.27 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Carbazoles
Direct Parent
Carbazoles
Alternative Parents
3-alkylindoles / Aralkylamines / Benzenoids / Pyrroles / Heteroaromatic compounds / Dialkylamines / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Carbazole / 3-alkylindole / Indole / Aralkylamine / Benzenoid / Heteroaromatic compound / Pyrrole / Azacycle / Secondary amine / Secondary aliphatic amine
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 23, 2015 16:13 / Updated on November 09, 2017 04:48